P. Richard Harrigan mainly focuses on Immunology, Virology, Acquired immunodeficiency syndrome, Viral load and Drug resistance. His Immunology research includes themes of Incidence and Cohort study. P. Richard Harrigan has included themes like Reverse transcriptase and Maraviroc in his Virology study.
P. Richard Harrigan combines subjects such as Viral disease and Mortality rate, Internal medicine with his study of Acquired immunodeficiency syndrome. The Viral load study combines topics in areas such as Genotyping and Genome. His Drug resistance research integrates issues from Odds ratio, HIV drug resistance, Antiretroviral therapy and Pharmacotherapy.
P. Richard Harrigan spends much of his time researching Virology, Immunology, Viral load, Internal medicine and Drug resistance. His work carried out in the field of Virology brings together such families of science as Genetics, Reverse transcriptase and Genotype. His research in Immunology intersects with topics in Prospective cohort study, Acquired immunodeficiency syndrome, Antiretroviral therapy and Cohort.
His work in Acquired immunodeficiency syndrome covers topics such as Viral disease which are related to areas like Immunopathology. His biological study spans a wide range of topics, including Viremia and Cohort study. His research in Drug resistance focuses on subjects like HIV drug resistance, which are connected to Protease inhibitor.
Virology, Drug resistance, Internal medicine, Acquired immunodeficiency syndrome and Viral load are his primary areas of study. His Virology study combines topics from a wide range of disciplines, such as Dolutegravir, First line and Genotype. His Drug resistance research is multidisciplinary, incorporating elements of Odds ratio, HIV drug resistance, Antiretroviral therapy, Cross-resistance and Data science.
In his study, Sexual transmission, Incidence and Psychological intervention is strongly linked to Harm reduction, which falls under the umbrella field of Acquired immunodeficiency syndrome. His Viral load study is concerned with the field of Immunology as a whole. His Immunology study frequently links to related topics such as Logistic regression.
P. Richard Harrigan focuses on Virology, Acquired immunodeficiency syndrome, Transmission, Drug resistance and Viral load. His studies deal with areas such as Longitudinal study, Dolutegravir, Antiretroviral therapy, T cell and Viral genetics as well as Virology. P. Richard Harrigan has researched Acquired immunodeficiency syndrome in several fields, including Effective population size, NS5B, Genotype, Hepacivirus and Epidemiological Monitoring.
His Drug resistance research incorporates elements of Sanger sequencing, Data science and Hiv resistance. His Viral load study contributes to a more complete understanding of Immunology. His study in the fields of Immune system under the domain of Immunology overlaps with other disciplines such as Disease cluster.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study
Julio S.G. Montaner;Julio S.G. Montaner;Julio S.G. Montaner;Viviane D. Lima;Viviane D. Lima;Rolando Barrios;Benita Yip.
The Lancet (2010)
Changes in Mitochondrial DNA as a Marker of Nucleoside Toxicity in HIV-Infected Patients
Hélène C F Côté;Zabrina L Brumme;Kevin J P Craib;Christopher S Alexander.
The New England Journal of Medicine (2002)
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic
Julio S. G. Montaner;Robert Hogg;Evan Wood;Thomas Kerr.
The Lancet (2006)
Predictors of HIV Drug-Resistance Mutations in a Large Antiretroviral-Naive Cohort Initiating Triple Antiretroviral Therapy
P. Richard Harrigan;Robert S. Hogg;Winnie W. Y. Dong;Benita Yip.
The Journal of Infectious Diseases (2005)
Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
Evan Wood;Robert S. Hogg;Benita Yip;P. Richard Harrigan.
Annals of Internal Medicine (2003)
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study
Evan Wood;Thomas Kerr;Brandon D L Marshall;Kathy Li.
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration
Rami Kantor;David A Katzenstein;Brad Efron;Ana Patricia Carvalho.
PLOS Medicine (2005)
Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.
David R Bangsberg;Edward P Acosta;Reena Gupta;David Guzman.
Expansion of HAART Coverage Is Associated with Sustained Decreases in HIV/AIDS Morbidity, Mortality and HIV Transmission: The “HIV Treatment as Prevention” Experience in a Canadian Setting
Julio S.G. Montaner;Viviane D. Lima;P. Richard Harrigan;Lillian Lourenço.
PLOS ONE (2014)
Molecular and Clinical Epidemiology of CXCR4-Using HIV-1 in a Large Population of Antiretroviral-Naive Individuals
Zabrina L. Brumme;Zabrina L. Brumme;James Goodrich;Howard B. Mayer;Chanson J. Brumme.
The Journal of Infectious Diseases (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: